Identification of the interplay between SOX9 and S100P in the metastasis and invasion of colon carcinoma

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20672-20684

  Shen, Zhiyong ^a   Deng, Haijun ^a   Fang, Yuan ^a   Zhu, Xianjun ^a   Ye, Geng tai ^a   Yan, Li ^a   Liu, Hao ^a   Li, Guoxin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Metastasis and invasion; S100P; SOX9; Transcriptional regulation

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCIUM BINDING PROTEIN; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN S100P; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; S100P PROTEIN, HUMAN; SOX9 PROTEIN, HUMAN; TUMOR PROTEIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CELL MIGRATION; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR INVASION; TUMOR PROMOTION; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; COLON TUMOR; GENETIC TRANSFECTION; GENETICS; HCT 116 CELL LINE; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

AGED; ANIMALS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HCT116 CELLS; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 84938827211     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3967     Document Type: Article

References (43)

1. Heizmann CW, Fritz G SB. S100 proteins: structure, functions and pathology. Front Biosci. 2002; 7:d1356-68.
2. Thomsen MK, Ambroisine L, Wynn S, Cheah KSE, Foster CS. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 2010; 70:979-87.
3. Matheu A, Collado M, Wise C, Manterola L, Cekaite L, Tye AJ, Canamero M, Bujanda L, Schedl A, Cheah KSE, Skotheim RI, Lothe Ra, De Munain AL, Briscoe J, Serrano M, Lovell-Badge R, López de Munain, Briscoe J, Serrano M, Lovell-Badge R, Munain AL De, Briscoe J, De Munain AL, Briscoe J, Serrano M, Lovell-Badge R. Oncogenicity of the developmental transcription factor Sox9. Cancer Res. 2012; 72:1301-15.
4. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zürrer-Härdi U, Bell G, Tam WL, Mani S a, van Oudenaarden A, Weinberg R a. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 2012; 148:1015-28.
5. Wang H, He L, Ma F, Regan MM, Balk SP, Richardson AL, Yuan X. SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer. J Biol Chem. 2013; 288:6478-87.
6. Ramalingam S, Daughtridge GW, Johnston MJ, GraczA D, Magness ST. Distinct levels of Sox9 expression mark colon epithelial stem cells that form colonoids in culture. Am J Physiol. 2012; 302:G10-20.
7. Feng Y, Sentani K, Wiese A, Sands E, Green M, Bommer GT, Cho KR, Fearon ER. Sox9 induction, ectopic Paneth cells, and mitotic spindle axis defects in mouse colon adenomatous epithelium arising from conditional biallelic Apc inactivation. Am J Pathol. 2013; 183:493-503.
8. Lin F, Shi J, Liu H, Hull ME, Dupree W, Prichard JW, Brown RE, Zhang J, Wang HL, Schuerch C. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am J Surg. Pathol. 2008; 32:78-91.
9. Dakhel S, Padilla L, Adan J, Masa M, Martinez JM, Roque L, Coll T, Hervas R, Calvis C, Messeguer R, Mitjans F, Hernández JL. S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer. Oncogenesis. 2014; 3:e92.
10. Whiteman HJ, Weeks ME, Dowen SE, Barry S, Timms JF, Lemoine NR, Crnogorac-Jurcevic T. The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res. 2007; 67:8633-42.
11. Hamada S, Satoh K, Hirota M, Kanno A, Ishida K, Umino J, Ito H, Kikuta K, Kume K, Masamune A, Katayose Y, Unno M, Shimosegawa T. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci. 2011; 102:150-6.
12. Aishima S, Fujita N, Mano Y, Kubo Y, Tanaka Y, Taketomi A, Shirabe K, Maehara Y, Oda Y. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am J Surg Pathol. 2011; 35:590-8.
13. Beissel B, Silva IDCG, Pesquero JB, Russo J, Schor N, Bellini MH. S-phase reduction in T47D human breast cancer epithelial cells induced by an S100P antisense-retroviral construct. Oncol Rep. 2007; 17:611-5.
14. Basu GD, Azorsa DO, Kiefer J a, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S. Functional evidence implicating S100P in prostate cancer progression. Int J cancer. 2008; 123:330-9.
15. Bartling B, Rehbein G, Simm A, Silber RE, Hofmann HS. Porcupine expression is associated with the expression of S100P and other cancer-related molecules in non-small cell lung carcinoma. Int J Oncol. 2010; 36:1015-21.
16. Jiang L, Lai YK, Zhang J, Wang H, Lin MC, He ML. Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis. Mol Med. 2011; 17:709-16.
17. Surowiak P, Maciejczyk a, Materna V, Drag-Zalesinska M, Wojnar a, Pudelko M, Kedzia W, Spaczynski M, Dietel M, Zabel M, Lage H. Unfavourable prognostic significance of S100P expression in ovarian cancers. Histopathology. 2007; 51:125-8.
18. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003; 63:2649-57.
19. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD, Diane M, Schmidt AM, Craig D, Simeone DM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem. 2004; 279:5059-65.
20. Gribenkoa V, Makhatadze GI. Oligomerization and divalent ion binding properties of the S100P protein: a Ca2+/Mg2+-switch model. J Mol Biol. 1998; 283:679-94.
21. Jin G, Wang S, Hu X, Jing Z, Chen J, Ying K, Xie Y, Mao Y. Characterization of the tissue-specific expression of the S100P gene which encodes an EF-hand Ca2+-binding protein. Mol Biol Rep. 2003; 30:243-8.
22. Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci. 1996; 21:134-40.
23. Heizmann CW, Ackermann GE, Galichet A. Pathologies involving the S100 proteins and RAGE. Subcell Biochem. 2007; 45:93-138.
24. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, Schmidt AM. RAGE is a multiligand receptor of the immunoglobulin superfamily: Implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 2002; 59:1117-28.
25. Hofmann M a, Drury S, Fu C, Qu W, Taguchi a, Lu Y, Avila C, Kambham N, Bierhaus a, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt a M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999; 97:889-901.
26. Koltzscher M, Neumann C, Ko S, Gerke V, König S, Gerke V, Ko S, Gerke V. Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol Biol Cell. 2003; 14:2372-84.
27. Peifer M. Wnt Signaling in Oncogenesis and Embryogenesis-a Look Outside the Nucleus. Science. 2000; 287:1606-9.
28. Fuchs SY, Ougolkov AV, Spiegelman VS. Oncogenic beta-catenin signaling networks in colorectal cancer. Cell cycle. 2005; 4:1522-39.
29. Namba T, Homan T, Nishimura T, Mima S, Hoshino T, Mizushima T. Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects. J Biol Chem. 2009; 284:4158-67.
30. Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H. In Vitro Degradation of Extracellular Matrix with M r 52,000 Cathepsin D Secreted by Breast Cancer Cells. Cancer Res. 1988; 3688-92.
31. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001; 33:637-68.
32. Hiwatashi K, Ueno S, Abeyama K, Kubo F, Sakoda M, Maruyama I, Hamanoue M, Natsugoe S, Aikou T. A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol. 2008; 15:923-33.
33. Mousses S, Bubendorf L, Wagner U. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 2002; 196:163-70.
34. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med. 2007; 7:777-89.
35. Tateno T, Ueno S, Hiwatashi K, Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Sakoda M, Kubo F, Ishigami S, Shinchi H, Natsugoe S. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2009; 16:440-6.
36. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst. 2006; 98:1806-18.
37. Arumugam T, Ramachandran V, Sun D, Peng Z, Pal A, Maxwell DS, Bornmann WG, Logsdon CD. Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. Mol Cancer Ther. 2013; 12:654-62.
38. Ling S, Chang X, Schultz L, Lee TK, Chaux A, Marchionni L, Netto GJ, Sidransky D, Berman DM. An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res. 2011; 71:3812-21.
39. Kim EK, Chio EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010; 1802:396-405.
40. Elsum I a, Martin C, Humbert PO. Scribble regulates an EMT polarity pathway through modulation of MAPK-ERK signaling to mediate junction formation. J Cell Sci. 2013; 126:3990-9.
41. Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R, Rudland PS. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 2006; 66:1199-207.
42. Goto Y, Ferrone S, Arigami T, Kitago M, Tanemura A, Sunami E, Nguyen SL, Turner RR, Morton DL, Hoon DSB. Human high molecular weight-melanoma-associated antigen: Utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res. 2008; 14:3401-7.
43. Guy CD, Suzuki A, Abdelmalek MF, Burchette JL, Diehl AM. Treatment Response in the PIVENS Trial is Associated with Decreased Hedgehog Pathway Activity. Hepatology. 2014; 019399:1-24.